These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 17562782

  • 1. The CHARM program: study design leads to findings of clinical and public health importance.
    Hennekens CH, Pfeffer MA, Swedberg K.
    J Cardiovasc Pharmacol Ther; 2007 Jun; 12(2):124-6. PubMed ID: 17562782
    [Abstract] [Full Text] [Related]

  • 2. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K, Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees.
    Circulation; 2004 Oct 26; 110(17):2618-26. PubMed ID: 15492298
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin inhibition in heart failure.
    McMurray JJ.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep 26; 5 Suppl 1():S17-22. PubMed ID: 15526237
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB.
    J Hypertens Suppl; 2006 Mar 26; 24(1):S3-7. PubMed ID: 16601570
    [Abstract] [Full Text] [Related]

  • 5. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, Earle S, Olofsson B, Ostergren J, Yusuf S, Swedberg K, Pfeffer MA, CHARM Investigators.
    Am Heart J; 2006 May 26; 151(5):985-91. PubMed ID: 16644319
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 26; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 7. Lack of deleterious interaction between angiotensin receptor blockers and beta-blockers in the treatment of patients with heart failure.
    Hennekens CH, Kowalczykowski M, Hollar D.
    J Cardiovasc Pharmacol Ther; 2006 Jun 26; 11(2):149-52. PubMed ID: 16891293
    [Abstract] [Full Text] [Related]

  • 8. The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Pocock S, Wang D, Wilhelmsen L, Hennekens CH.
    Am Heart J; 2005 May 26; 149(5):939-43. PubMed ID: 15894981
    [Abstract] [Full Text] [Related]

  • 9. [Angiotensin receptor blockers in heart failure. CHARM Study].
    Kochsiek K.
    Internist (Berl); 2004 Sep 26; 45(9):1063-7. PubMed ID: 15309315
    [No Abstract] [Full Text] [Related]

  • 10. [CHARM study--new strategy for the treatment of heart failure].
    Hasegawa H, Komuro I.
    Nihon Rinsho; 2004 May 26; 62(5):995-1002. PubMed ID: 15148833
    [Abstract] [Full Text] [Related]

  • 11. Initial data supporting the design of the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    McKelvie RS.
    J Hypertens Suppl; 2006 Mar 26; 24(1):S9-13. PubMed ID: 16601580
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, Yusuf S, Michelson EL, Swedberg K, Pfeffer MA, CHARM Investigators.
    Eur J Heart Fail; 2008 Feb 26; 10(2):157-63. PubMed ID: 18242128
    [Abstract] [Full Text] [Related]

  • 13. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
    McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA, CHARM Investigators and Committees.
    Lancet; 2003 Sep 06; 362(9386):767-71. PubMed ID: 13678869
    [Abstract] [Full Text] [Related]

  • 14. Exploring new treatment strategies in heart failure.
    Swedberg K.
    Blood Press Suppl; 2000 Sep 06; 1():44-8. PubMed ID: 11059637
    [Abstract] [Full Text] [Related]

  • 15. [AT1 blockers against heart failure. The charm of polypharmacy].
    MMW Fortschr Med; 2003 Sep 18; 145(38):6. PubMed ID: 14603670
    [No Abstract] [Full Text] [Related]

  • 16. The CHARM program: the effects of candesartan for the management of patients with chronic heart failure.
    McKelvie RS.
    Expert Rev Cardiovasc Ther; 2009 Jan 18; 7(1):9-16. PubMed ID: 19105762
    [Abstract] [Full Text] [Related]

  • 17. [Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].
    Rakugi H, Ogihara T.
    Nihon Rinsho; 2001 Oct 18; 59(10):2051-61. PubMed ID: 11676153
    [Abstract] [Full Text] [Related]

  • 18. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
    Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Yusuf S.
    Am Heart J; 2006 May 18; 151(5):985-91. PubMed ID: 16644318
    [Abstract] [Full Text] [Related]

  • 19. A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
    Erhardt LR.
    Int J Clin Pract; 2005 May 18; 59(5):571-8. PubMed ID: 15857354
    [Abstract] [Full Text] [Related]

  • 20. ACE inhibitors in heart failure: what more do we need to know?
    Demers C, Mody A, Teo KK, McKelvie RS.
    Am J Cardiovasc Drugs; 2005 May 18; 5(6):351-9. PubMed ID: 16259523
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.